Sign in

You're signed outSign in or to get full access.

John Grampa

Director at PARK OHIO HOLDINGS
Board

About John D. Grampa

Independent director at Park-Ohio Holdings Corp. (PKOH) since 2015; age 77; former Senior Vice President, Finance and CFO at Materion Corporation, with prior senior finance roles at Avery Dennison and Diamond Shamrock. He serves as Chair of the Audit Committee and is designated by the Board as the Audit Committee financial expert under SEC rules. Tenure on PKOH’s Board is ~10 years as of the 2025 proxy.

Past Roles

OrganizationRoleTenureCommittees/Impact
Materion CorporationSenior Vice President, Finance & CFO; later SVP, AdministrationCFO Dec 2006–Jan 2015; SVP, Administration until Sep 2015Led finance; M&A experience cited as qualification for PKOH board and Audit leadership
Materion CorporationVP Finance; CFO since 1999; VP Finance since 19981998–2015Broad financial management responsibilities
Avery Dennison (Worldwide Materials)Vice President, Finance and other financial management roles1984–1998Global finance leadership in manufacturing
Diamond ShamrockVarious financial management rolesSince Feb 1970 (historic)Industrial/specialty chemicals/plastics/oil & gas finance experience

External Roles

OrganizationRoleTenureNotes
No other current public company directorships disclosed in PKOH 2025 proxy biography

Board Governance

  • Independence: The Board determined Mr. Grampa is independent under Nasdaq rules; he is the Board-designated audit committee financial expert.
  • Committee assignments: Audit Committee Chair; members include Messrs. Grampa, Hanna, Rosen, and Wert.
  • Meeting cadence and attendance: Board met 5 times in 2024; Audit Committee met 8 times; no director attended less than 75% of aggregate Board/committee meetings; all directors attended the 2024 annual meeting.
  • Audit Committee report: As Chair, Mr. Grampa co-signed the Audit Committee Report recommending inclusion of audited financials in the 2024 Form 10-K.
  • Leadership structure context: Lead Independent Director is James W. Wert; independent executive sessions overseen by Lead Director.

Fixed Compensation

Director compensation structure and Mr. Grampa’s actual pay:

Item20232024
Cash retainer (policy)$50,000 per non-employee director $50,000 per non-employee director
Board meeting fees (policy)$4,000 in-person; $1,000 telephonic/electronic $4,000 in-person; $1,000 telephonic/electronic
Committee meeting fees (policy)$1,000 per committee meeting $1,000 per committee meeting
Committee chair retainer (policy)$15,000 for Audit, Compensation, Nominating/CG Chairs $25,000 for Audit and Compensation Chairs; $15,000 Nominating/CG Chair
Mr. Grampa – Fees earned (cash)$88,000 $96,000
Total director stock grant (policy)6,000 restricted shares (or units) 4,350 restricted shares (or units)
Mr. Grampa – Total compensation$182,620 (cash $88,000; stock $94,620) $206,186 (cash $96,000; stock $110,186)

Notes:

  • 2024 equity grants generally vest one year from grant date (June 26, 2024); 2023 grants vested one year from grant date (May 31, 2023).

Performance Compensation

ComponentMetric/TermsGrant DateGrant Value
Restricted shares/units (annual director grant)Time-based vesting; no performance metrics disclosed2023: May 31, 2023; 2024: June 26, 20242023: 6,000 shares, $94,620; 2024: 4,350 shares/units, $110,186
Options/PSUs to directorsNot disclosed for directors in 2023–2024; annual director equity reported as restricted shares/units
Plan features (context)Amended 2021 Plan permits RSUs, options, SARs, PS/PU, cash awards; minimum 1-year vesting generally; non-employee director annual comp cap $500,000 (grant-date fair value)Amended 2021 Plan last amended effective May 15, 2025Plan capacity/limits as disclosed
  • Awards to 2025 director nominees: Each of John D. Grampa and Steven H. Rosen is shown with 18,620 restricted shares/units in the “Awards Granted to Certain Persons” table under the Amended 2021 Plan proposal.

Other Directorships & Interlocks

CompanyRoleCommittee rolesInterlocks/Conflicts
None disclosed for Mr. Grampa; Compensation Committee interlocks section identifies only Ms. Romney and Mr. Rosen as members and reports no interlocks in 2024.

Expertise & Qualifications

  • Broad-based strategic operations and finance background across three global manufacturers; extensive acquisition and financial management experience.
  • Board-designated Audit Committee financial expert; aligns with role as Audit Committee Chair overseeing financial reporting, internal controls, and auditor independence.

Equity Ownership

As of March 21, 2025:

HolderShares OwnedShares Acquirable Within 60 DaysPercent of Class
John D. Grampa11,350 35,776 (restricted share units deliverable upon separation of service) <1%

Policy context:

  • Anti-hedging and limited pledging policy applies to directors; pledging only with pre-approval and limits. No pledging by Mr. Grampa is disclosed.

Insider Trades

Transaction DateFiling DateSecurityAmount/TypeNotes
Aug 16, 2024Aug 21, 2024Restricted Stock Units151 acquiredOne Form 4 filed late; disclosed under Section 16(a) delinquent reports

Governance Assessment

  • Strengths: Independent director, Audit Committee Chair, and SEC “audit committee financial expert”; strong committee engagement (8 Audit meetings in 2024) and Board attendance standards met; equity compensation mix (~52–53% equity of total director pay in 2023–2024) promotes alignment; hedging prohibited and pledging restricted; director annual compensation capped under equity plan.
  • Watchpoints: Minor Section 16(a) timeliness lapse (late Form 4 for 151 RSUs on Aug 16, 2024, filed Aug 21, 2024). While not material alone, it is a compliance footnote to monitor.
  • Related-party environment (not involving Mr. Grampa): Board oversees related-party transactions including aircraft and facility leases with entities owned by Messrs. Matthew and Edward Crawford and product purchases by Crawford United (with Mr. Rosen as a shareholder/director). Heightens the importance of robust Audit Committee oversight of conflicts.
  • Shareholder sentiment context: Say-on-pay approval in 2023 was ~73%, indicating room for continued engagement (next SOP in 2026).